Crohn's disease trials in Israel

In Israel 32 Also abroad 422

32 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
No phaseTaking people
IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome
Where
Ramat Gan
Age
18 years and over
People
150
Run by
Ariel University
See details and how to joinNCT07707635
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Ashdod, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 2Taking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Beersheba, Be’er Ya‘aqov, Jerusalem, Petah Tikva, Rehovot
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Jerusalem
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Ashdod, Haifa, Holon/Tel Aviv, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv, Yeruham
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Ashdod, Beersheba, Jerusalem, Kfar Saba, Ramat Gan
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Where
Ashdod
Age
18 years to 75 years
People
2,000 worldwide
Run by
AbbVie
See details and how to joinNCT07697456 · EU 2026-525959-86-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Jerusalem
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Afula, Ashkelon, Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Jerusalem, Tel Aviv
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Jerusalem, Petah Tikva
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Beersheba, Haifa, Jerusalem, Ramat Gan
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Beersheba, Haifa, Jerusalem, Petah Tikva, Tsrifin
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Beersheba, Israel, Jerusalem, Petah Tikva, Rehovot
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Beersheba, Haifa, Holon, Tel Aviv
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
No phaseTaking people
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
Where
Afula
Age
18 years and over
People
40 worldwide
Run by
Weizmann Institute of Science
See details and how to joinNCT06494826
Phase 2Taking people
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
Where
Beersheba, Haifa, Holon, Jerusalem, Kiryat Bialik, Petah Tikva
Age
18 years and over
People
180
Run by
Rambam Health Care Campus
See details and how to joinNCT05599347
No phaseTaking people
Impact of Advanced Crohn's Disease Therapies on Sleep Quality
Where
Tel Aviv
Age
18 years and over
People
30
Run by
Shmuel Kivity, MD
See details and how to joinNCT07649408
No phaseTaking people
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
Where
Tel Aviv
Age
18 years and over
People
40
Run by
Shmuel Kivity, MD
See details and how to joinNCT07644117
Phase 3Taking people
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Where
Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv
Age
18 years to 65 years
People
396 worldwide
Run by
Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00
Phase 3Taking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Beersheba, Haifa, Jerusalem, Petah Tikva
Age
2 years to 17 years
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00